Further evidence for differences between non-selective and BZ-1 (ω1) selective, benzodiazepine receptor ligands in murine models of 'state' and 'trait' anxiety

Neuropharmacology

Volumn 35, Issue 8, 1996, Pages 1081-1091

  Griebel, G ^a   Sanger, D J ^a   Perrault, G ^a  

^a SANOFI   (France)

Author keywords

'Trait' and 'state' anxiety; BALB c mice; Benzodiazepines; BZ ( ) receptor; Free exploration test; Light dark choice task; Risk assessment

Indexed keywords

3 METHYL 6 (3 TRIFLUOROMETHYLPHENYL) 1,2,4 TRIAZOLO[4,3 B]PYRIDAZINE; ABECARNIL; ALPRAZOLAM; ANXIOLYTIC AGENT; BENZODIAZEPINE RECEPTOR; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; BRETAZENIL; CHLORDIAZEPOXIDE; CLORAZEPATE; DIAZEPAM; IMIDAZENIL; RO 19 8022; UNCLASSIFIED DRUG; ZOLPIDEM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; BEHAVIOR; CONTROLLED STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANXIETY; CHOICE BEHAVIOR; DOSE-RESPONSE RELATIONSHIP, DRUG; EXPLORATORY BEHAVIOR; LIGANDS; MALE; MICE; MICE, INBRED BALB C; MOTOR ACTIVITY; RECEPTORS, GABA-A;

EID: 0030445551     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(96)00080-9     Document Type: Article

References (48)

1. Belzung C., Misslin R., Vogel E., Dodd R. H. and Chapouthier G. (1987) Anxiogenic effects of methyl-beta-carboline-3-carboxylate in a light/dark choice situation. Pharmacol. Biochem. Behav. 28: 29-33.
2. Beizung, C. (1988) Utilisation d'un test de conflit non conditionné chez la souris pour l'étude des propriétés anxiolytiques et anxiogènes de substances intéragissant avec le complexe récepteur GABA-benzodiazépines, Thèse d'Université, Université Louis Pasteur, Strasbourg.
3. Belzung C., Pineau N., Beuzen A. and Misslin R. (1994) PD135158, a CCK-B antagonist, reduces "state", but not "trait" anxiety in mice. Pharmacol. Biochem. Behav. 49: 433-436.
4. Belzung C. and Le Pape G. (1994) Comparison of different behavioral test situations used in psychopharmacology for measurement of anxiety. Physiol. Behav. 56: 623-628.
5. Belzung C., Misslin R. and Vogel E. (1989) Behavioural effects of the benzodiazepine receptor partial agonist RO 16-6028 in mice. Psychopharmacology 97: 388-391.
6. Beuzen A. and Belzung C. (1995) Link between emotional memory and anxiety states: a study by principal component analysis. Physiol Behav. 58: 111-118.
7. Blanchard, D. C., Blanchard, R. J. and Rodgers, R. J. (1991) Risk assessment and animal models of anxiety. In: Animal Models in Psychopharmacology, (Olivier B., Mos J. and Slangen J. L., Eds), pp 117-134. Birkhauser Verlag AG, Basel.
8. Costall B., Jones B. J., Kelly M. E., Naylor R. J. and Tomkins D. M. (1989) Exploration of mice in a black and white test box: validation as a model of anxiety. Pharmacol. Biochem. Behav. 32: 777-785.
9. Crawley J. and Goodwin F. K. (1980) Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines. Pharmacol. Biochem. Behav. 13: 167-170.
10. Deacon R. M. J., Guy A. P. and Gardner C. R. (1991) Effects of selected imidazopyrimidine ligands for benzodiazepine receptors in rodent models of anxiety and behavioural impairment. Drug Dev. Res. 22: 321-329.
11. Depoortere H., Zivkovic B., Lloyd K. G., Sanger D. J., Perrault G., Langer S. Z. and Bartholini G. (1986) Zolpidem, a novel non-benzodiazepine hypnotic: I. Neuropharmacological and behavioral effects. J. Pharmacol Exp. Ther. 237: 649-658.
12. A receptor. Eur. J. Pharmacol. 246: 283-287.
13. A receptors. J. Pharmacol. Exp. Ther. 266: 1018-1028.
14. 1A agonist, S20244, and its enantiomers in mice. Neuroreport. 3: 84-86.
15. Griebel G., Belzung C., Misslin R. and Vogel E. (1993) The free-exploratory paradigm: an effective method for measuring neophobic behaviour in mice and testing potential neophobia-reducing drugs. Behav. Pharmacol. 4: 637-644.
16. Griebel, G., Sanger, D. J. and Perrault, G. (1996) The use of the rat elevated plus-maze to discriminate between non-selective and BZ-1 (ω1) selective, benzodiazepine receptor ligands. Psychopharmacology, 124: 245-254.
17. Haefely W., Martin J. R. and Schoch P. (1990) Novel anxiolytics that acts as partial agonists at benzodiazepine receptors. Trends Pharmacol. Sci. 11: 452-456.
18. Jenck F., Moreau J. L., Bonetti E. P., Martin J. R. and Haefely W. E. (1992) Ro 19-8022, a nonbenzodiazepine partial agonist at benzodiazepine receptors: neuropharmacological profile of a potential anxiolytic. J. Pharmacol. Exp. Ther. 262: 1121-1127.
19. Jones G. H., Schneider C., Schneider H. H., Seidler J., Cole B. J. and Stephens D. N. (1994) Comparison of several benzodiazepine receptor ligands in two models of anxiolytic activity in the mouse: An analysis based on fractional receptor occupancies. Psychopharmacology 114: 191-199.
20. A receptor. J. Pharmacol. Exp. Ther. 266: 385-391.
21. Langer S. Z. and Arbilla S. (1988) Imidazopyridines as a tool for the characterization of benzodiazepine receptors: a proposal for a pharmacological classification as omega receptor subtypes. Pharmacol. Biochem. Behav. 29: 763-766.
22. Lister R. G. (1990) Ethologically-based animal models of anxiety disorders. Pharmacol. Ther. 46: 321-340.
23. Makino J., Kato K. and Macs F. W. (1991) Temporal structure of open-field behaviour in inbred strains of mice. Japan. Psychol. Res. 33: 145-152.
24. Martin J. R., Pieri L., Bonetti E. P., Schaffner R., Burkard W. P., Cumin R. and Haefely W. E. (1988) Ro 16-6028: a novel anxiolytic acting as a partial agonist at the benzodiazepine receptor. Pharmacopsychiatry 21: 360-362.
25. Martin J. R., Schoch P., Jenck F., Moreau J.-L. and Haefely W. E. (1993) Pharmacological characterization of benzodiazepine receptor ligands with intrinsic efficacies ranging from high to zero. Psychopharmacology 111: 415-422.
26. 1A ligands, 8-OH-DPAT and MDL 73005EF, in mice. Neuroreport 1: 267-270.
27. Misslin R., Belzung C. and Vogel E. (1989) Behavioural validation of a light/dark choice procedure for testing anti-anxiety agents. Behav. Process. 8: 119-132.
28. Misslin R. and Cigrang M. (1986) Does neophobia necessarily imply fear or anxiety? Behav. Process. 12: 45-50.
29. A receptor subtypes. In: Anxiolytic β-carbolines, (Stephens D. N., Ed.), pp. 50-61. Springer-Verlag, Berlin.
30. A-benzodiazepine receptors produced in transfected cells. Science 245: 1389-1392.
31. A receptor α5-subunit creates novel type II benzodiazepine receptor pharmacology. J. Neurochem. 54: 1802-1804.
32. Puia G., Ducic I., Vicini S. and Costa E. (1992) Molecular mechanisms of the partial allosteric modulatory effects of bretazenil at gamma-aminobutyric acid type A receptor. Proc. Natl Acad. Sci. U.S.A. 89: 3620-3624.
33. Rijnders H. J., Jarbe T. U. and Slangen J. L. (1991) The pentylenetetrazole-cue antagonist actions of bretazenil (Ro 16-6028) as compared to midazolam. Pharmacol. Biochem. Behav. 39: 129-132.
34. Robertson H. A. (1979) Benzodiazepine receptors in "emotional" and "non emotional" mice: comparison of four strains. Eur. J. Pharmacol. 56: 163-166.
35. Rodgers, R. J. and Cole, J. C. (1994) The elevated plus-maze: pharmacology, methodology and ethology. In: Ethology and Psychopharmacology, (Cooper S. J. and Hendrie C. A., Eds), pp. 9-44. John Wiley and Sons Ltd, Chichester, U.K.
36. Sanger D. J., Perrault G., Morel E., Joly D. and Zivkovic B. (1991) Animal models of anxiety and the development of novel anxiolytic drugs. Prog. Neuropsychopharmacol Biol. Psychiatry 15: 205-212.
37. Sanger D. J., Benavides J., Perrault G., Morel E., Cohen C., JoIy D. and Zivkovic B. (1994) Recent developments in the behavioral pharmacology of benzodiazepine (ω) receptors: Evidence for the functional significance of receptor subtypes. Neurosci. Biobehav. Rev. 18: 355-372.
38. Sanger D. J. (1995) The behavioural effects of novel benzodiazepine (ω) receptor agonists and partial agonists: Increases in punished responding and antagonism of the pentylenetetrazole cue. Behav. Pharmacol. 6: 116-126.
39. Sanger D. J., Joly D. and Perrault G. (1995) Benzodiazepine (ω) receptor partial agonists and the acquisition of conditioned fear in mice. Psychopharmacology 121: 104-108.
40. Sanger D. J. and Zivkovic B. (1988) Further behavioural evidence for the selective sedative action of zolpidem. Neuropharm. 27: 1125-1130.
41. A receptor subtypes. Pharmacol. Rev. 47: 181-234.
42. Sieghart W. and Schuster A. (1984) Affinity of various ligands for benzodiazepine receptors in rat cerebellum and hippocampus. Pharmacol. Biochem. Behav. 33: 4033-4038.
43. Squires R. F., Benson D. I., Braestrup C., Coupet J., Klepner C. A., Myers V. and Beer B. (1979) Some properties of brain specific benzodiazepine receptors: new evidence for multiple receptors. Pharmacol. Biochem. Behav. 10: 825-830.
44. Stephens D. N., Schneider H. H., Kehr W., Andrews J. S., Rettig K. J., Turski L., Schmiechen R., Turner J. D., Jensen L. H. and Petersen E. N. (1990) Abecarnil, a metabolically stable, anxioselective β-carboline acting at benzodiazepine receptors. J. Pharmacol Exp. Ther. 253: 334-343.
45. Stephens D. N. and Voet B. (1994) Differential effects of anxiolytic and non-anxiolytic benzodiazepine receptor ligands on performance of a differential reinforcement of low rate (DRL) schedule. Behav. Pharmacol. 5: 4-14.
46. Treit D. (1985) Animal models for the study of anti-anxiety agents: a review. Neurosci. Biobehav. Rev. 9: 203-222.
47. Trullas R. and Skolnick P. (1993) Differences in fear motivated behaviors among inbred mouse strains. Psychopharmacology 111: 323-331.
48. Wafford K. A., Whiting P. J. and Kemp J. A. (1993) Differences in affinity and efficacy of benzodiazepine receptor ligands at recombinant gamma-aminobutyric acid receptor subtypes. Mol. Pharmacol. 43: 240-244.